Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities
Summary Background/aims: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. In many patients, the disease is complicated by enhanced susceptibility to skin infections, especially with Staphylococcus aureus. The aim of this study was to determine the antimicrobial susceptibility o...
Gespeichert in:
| Veröffentlicht in: | Experimental dermatology 2008-11, Vol.17 (11), p.953-957 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 957 |
|---|---|
| container_issue | 11 |
| container_start_page | 953 |
| container_title | Experimental dermatology |
| container_volume | 17 |
| creator | Niebuhr, Margarete Mai, Uwe Kapp, Alexander Werfel, Thomas |
| description | Summary
Background/aims: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. In many patients, the disease is complicated by enhanced susceptibility to skin infections, especially with Staphylococcus aureus. The aim of this study was to determine the antimicrobial susceptibility of skin‐colonizing S. aureus strains in patients with AD and consecutively to recommend the first‐line antibiotic therapy.
Methods: We studied S. aureus‐positive skin swabs (n = 102) from lesional skin of children, adolescents and adults with AD presenting to our inpatient and outpatient departments from January 2005 to June 2006.
Results: Antimicrobial susceptibility testing revealed resistance against oxacillin, amoxicillin/clavulanic acid, cephalexin and cefuroxim in 3%, against tetracycline in 17%, against gentamicin in 16%, against erythromycin and clindamycin in 21%, against trimethoprim/sulfamethoxazol in 23%, against levofloxacin in 23%, against fusidic acid in 25%, against fosfomycin in 12% and against rifampicin in 16%. All strains isolated were susceptible to vancomycin.
Conclusion: Currently, the first generation cephalosporin cephalexin appears to be the preferential first‐line antibiotic for the treatment of bacterial superinfections with S. aureus in children and adults with AD due to its restricted antimicrobial spectrum to Gram‐positive bacteria and a limited number of Gram‐negative strains. Cefuroxim and amoxicillin/clavulanate, which also showed 3% resistances in our patients, cover a broader range of bacterial micro‐organisms. However, a broader coverage is not required in case of AD, as S. aureus is the most frequent bacterial micro‐organism causing skin infections. |
| doi_str_mv | 10.1111/j.1600-0625.2008.00734.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69740472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69740472</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4654-3b444ce9f14b49a81a3e7aa8ff1b258e0ca8a058e13612df48a4b76cd5533d203</originalsourceid><addsrcrecordid>eNqNkk-P1CAYxhujccfVr2C46K0VCoVivGzWnVnjRg-u0RuhlGYZ-2-BZme-jp_Ut9tmPCoXCPye533hIUkQwRmB8W6fEY5xinleZDnGZYaxoCw7PEk2p4OnyQZLzFMucHGWvAhhjzERVBTPkzNSFoWQudwkvy_66Co3RGdQ9FbHzvYRDQ0yU9S9HaaAXN9YE93QB_Tg4h36FvV4d2wHMxgDx3ry9pFCo44O1Cum4zCCaW19B_vRhffg6f1sr6Fm54wfKqdb5G1wAYoZC2Z9jcIUjB3nrlqQ2fAyedboNthX63yefN9e3V5epzdfd58uL25Sw3jBUloxxoyVDWEVk7okmlqhddk0pMqL0mKjS41hQSgned2wUrNKcFMXBaV1jul58nbxHf1wP9kQVeegk7Zd3kFxKRhmIv8nSCTnmJYMwHIB4aoheNuo0btO-6MiWM1Bqr2a81JzXmoOUj0GqQ4gfb3WmKrO1n-Fa3IAvFkBHYxuGw8P6MKJy7EQjEsK3IeFe3CtPf53A-rq50dYgDxd5BCRPZzk2v9SfP5M6seXndpuP19LubtVW_oH0LPNfQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19660384</pqid></control><display><type>article</type><title>Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Niebuhr, Margarete ; Mai, Uwe ; Kapp, Alexander ; Werfel, Thomas</creator><creatorcontrib>Niebuhr, Margarete ; Mai, Uwe ; Kapp, Alexander ; Werfel, Thomas</creatorcontrib><description>Summary
Background/aims: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. In many patients, the disease is complicated by enhanced susceptibility to skin infections, especially with Staphylococcus aureus. The aim of this study was to determine the antimicrobial susceptibility of skin‐colonizing S. aureus strains in patients with AD and consecutively to recommend the first‐line antibiotic therapy.
Methods: We studied S. aureus‐positive skin swabs (n = 102) from lesional skin of children, adolescents and adults with AD presenting to our inpatient and outpatient departments from January 2005 to June 2006.
Results: Antimicrobial susceptibility testing revealed resistance against oxacillin, amoxicillin/clavulanic acid, cephalexin and cefuroxim in 3%, against tetracycline in 17%, against gentamicin in 16%, against erythromycin and clindamycin in 21%, against trimethoprim/sulfamethoxazol in 23%, against levofloxacin in 23%, against fusidic acid in 25%, against fosfomycin in 12% and against rifampicin in 16%. All strains isolated were susceptible to vancomycin.
Conclusion: Currently, the first generation cephalosporin cephalexin appears to be the preferential first‐line antibiotic for the treatment of bacterial superinfections with S. aureus in children and adults with AD due to its restricted antimicrobial spectrum to Gram‐positive bacteria and a limited number of Gram‐negative strains. Cefuroxim and amoxicillin/clavulanate, which also showed 3% resistances in our patients, cover a broader range of bacterial micro‐organisms. However, a broader coverage is not required in case of AD, as S. aureus is the most frequent bacterial micro‐organism causing skin infections.</description><identifier>ISSN: 0906-6705</identifier><identifier>EISSN: 1600-0625</identifier><identifier>DOI: 10.1111/j.1600-0625.2008.00734.x</identifier><identifier>PMID: 18557929</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Allergic diseases ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; antimicrobial susceptibility ; atopic dermatitis ; Bacterial diseases ; Biological and medical sciences ; Child ; Child, Preschool ; Dermatitis, Atopic - complications ; Dermatology ; Drug Resistance, Bacterial ; Female ; Human bacterial diseases ; Humans ; Immunopathology ; Infant ; Infectious diseases ; Male ; Medical sciences ; Microbial Sensitivity Tests ; Middle Aged ; Retrospective Studies ; Skin allergic diseases. Stinging insect allergies ; Staphylococcal infections, streptococcal infections, pneumococcal infections ; Staphylococcal Skin Infections - complications ; Staphylococcal Skin Infections - drug therapy ; Staphylococcal Skin Infections - microbiology ; Staphylococcus aureus ; Staphylococcus aureus - drug effects ; Staphylococcus aureus - isolation & purification ; Vancomycin - pharmacology ; Vancomycin - therapeutic use ; Young Adult</subject><ispartof>Experimental dermatology, 2008-11, Vol.17 (11), p.953-957</ispartof><rights>2008 The Authors. Journal compilation © 2008 Blackwell Munksgaard</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4654-3b444ce9f14b49a81a3e7aa8ff1b258e0ca8a058e13612df48a4b76cd5533d203</citedby><cites>FETCH-LOGICAL-c4654-3b444ce9f14b49a81a3e7aa8ff1b258e0ca8a058e13612df48a4b76cd5533d203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1600-0625.2008.00734.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1600-0625.2008.00734.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20774693$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18557929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niebuhr, Margarete</creatorcontrib><creatorcontrib>Mai, Uwe</creatorcontrib><creatorcontrib>Kapp, Alexander</creatorcontrib><creatorcontrib>Werfel, Thomas</creatorcontrib><title>Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities</title><title>Experimental dermatology</title><addtitle>Exp Dermatol</addtitle><description>Summary
Background/aims: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. In many patients, the disease is complicated by enhanced susceptibility to skin infections, especially with Staphylococcus aureus. The aim of this study was to determine the antimicrobial susceptibility of skin‐colonizing S. aureus strains in patients with AD and consecutively to recommend the first‐line antibiotic therapy.
Methods: We studied S. aureus‐positive skin swabs (n = 102) from lesional skin of children, adolescents and adults with AD presenting to our inpatient and outpatient departments from January 2005 to June 2006.
Results: Antimicrobial susceptibility testing revealed resistance against oxacillin, amoxicillin/clavulanic acid, cephalexin and cefuroxim in 3%, against tetracycline in 17%, against gentamicin in 16%, against erythromycin and clindamycin in 21%, against trimethoprim/sulfamethoxazol in 23%, against levofloxacin in 23%, against fusidic acid in 25%, against fosfomycin in 12% and against rifampicin in 16%. All strains isolated were susceptible to vancomycin.
Conclusion: Currently, the first generation cephalosporin cephalexin appears to be the preferential first‐line antibiotic for the treatment of bacterial superinfections with S. aureus in children and adults with AD due to its restricted antimicrobial spectrum to Gram‐positive bacteria and a limited number of Gram‐negative strains. Cefuroxim and amoxicillin/clavulanate, which also showed 3% resistances in our patients, cover a broader range of bacterial micro‐organisms. However, a broader coverage is not required in case of AD, as S. aureus is the most frequent bacterial micro‐organism causing skin infections.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Allergic diseases</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>antimicrobial susceptibility</subject><subject>atopic dermatitis</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Dermatitis, Atopic - complications</subject><subject>Dermatology</subject><subject>Drug Resistance, Bacterial</subject><subject>Female</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>Infant</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Skin allergic diseases. Stinging insect allergies</subject><subject>Staphylococcal infections, streptococcal infections, pneumococcal infections</subject><subject>Staphylococcal Skin Infections - complications</subject><subject>Staphylococcal Skin Infections - drug therapy</subject><subject>Staphylococcal Skin Infections - microbiology</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Staphylococcus aureus - isolation & purification</subject><subject>Vancomycin - pharmacology</subject><subject>Vancomycin - therapeutic use</subject><subject>Young Adult</subject><issn>0906-6705</issn><issn>1600-0625</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk-P1CAYxhujccfVr2C46K0VCoVivGzWnVnjRg-u0RuhlGYZ-2-BZme-jp_Ut9tmPCoXCPye533hIUkQwRmB8W6fEY5xinleZDnGZYaxoCw7PEk2p4OnyQZLzFMucHGWvAhhjzERVBTPkzNSFoWQudwkvy_66Co3RGdQ9FbHzvYRDQ0yU9S9HaaAXN9YE93QB_Tg4h36FvV4d2wHMxgDx3ry9pFCo44O1Cum4zCCaW19B_vRhffg6f1sr6Fm54wfKqdb5G1wAYoZC2Z9jcIUjB3nrlqQ2fAyedboNthX63yefN9e3V5epzdfd58uL25Sw3jBUloxxoyVDWEVk7okmlqhddk0pMqL0mKjS41hQSgned2wUrNKcFMXBaV1jul58nbxHf1wP9kQVeegk7Zd3kFxKRhmIv8nSCTnmJYMwHIB4aoheNuo0btO-6MiWM1Bqr2a81JzXmoOUj0GqQ4gfb3WmKrO1n-Fa3IAvFkBHYxuGw8P6MKJy7EQjEsK3IeFe3CtPf53A-rq50dYgDxd5BCRPZzk2v9SfP5M6seXndpuP19LubtVW_oH0LPNfQ</recordid><startdate>200811</startdate><enddate>200811</enddate><creator>Niebuhr, Margarete</creator><creator>Mai, Uwe</creator><creator>Kapp, Alexander</creator><creator>Werfel, Thomas</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200811</creationdate><title>Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities</title><author>Niebuhr, Margarete ; Mai, Uwe ; Kapp, Alexander ; Werfel, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4654-3b444ce9f14b49a81a3e7aa8ff1b258e0ca8a058e13612df48a4b76cd5533d203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Allergic diseases</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>antimicrobial susceptibility</topic><topic>atopic dermatitis</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Dermatitis, Atopic - complications</topic><topic>Dermatology</topic><topic>Drug Resistance, Bacterial</topic><topic>Female</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>Infant</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Skin allergic diseases. Stinging insect allergies</topic><topic>Staphylococcal infections, streptococcal infections, pneumococcal infections</topic><topic>Staphylococcal Skin Infections - complications</topic><topic>Staphylococcal Skin Infections - drug therapy</topic><topic>Staphylococcal Skin Infections - microbiology</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Staphylococcus aureus - isolation & purification</topic><topic>Vancomycin - pharmacology</topic><topic>Vancomycin - therapeutic use</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niebuhr, Margarete</creatorcontrib><creatorcontrib>Mai, Uwe</creatorcontrib><creatorcontrib>Kapp, Alexander</creatorcontrib><creatorcontrib>Werfel, Thomas</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niebuhr, Margarete</au><au>Mai, Uwe</au><au>Kapp, Alexander</au><au>Werfel, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities</atitle><jtitle>Experimental dermatology</jtitle><addtitle>Exp Dermatol</addtitle><date>2008-11</date><risdate>2008</risdate><volume>17</volume><issue>11</issue><spage>953</spage><epage>957</epage><pages>953-957</pages><issn>0906-6705</issn><eissn>1600-0625</eissn><abstract>Summary
Background/aims: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. In many patients, the disease is complicated by enhanced susceptibility to skin infections, especially with Staphylococcus aureus. The aim of this study was to determine the antimicrobial susceptibility of skin‐colonizing S. aureus strains in patients with AD and consecutively to recommend the first‐line antibiotic therapy.
Methods: We studied S. aureus‐positive skin swabs (n = 102) from lesional skin of children, adolescents and adults with AD presenting to our inpatient and outpatient departments from January 2005 to June 2006.
Results: Antimicrobial susceptibility testing revealed resistance against oxacillin, amoxicillin/clavulanic acid, cephalexin and cefuroxim in 3%, against tetracycline in 17%, against gentamicin in 16%, against erythromycin and clindamycin in 21%, against trimethoprim/sulfamethoxazol in 23%, against levofloxacin in 23%, against fusidic acid in 25%, against fosfomycin in 12% and against rifampicin in 16%. All strains isolated were susceptible to vancomycin.
Conclusion: Currently, the first generation cephalosporin cephalexin appears to be the preferential first‐line antibiotic for the treatment of bacterial superinfections with S. aureus in children and adults with AD due to its restricted antimicrobial spectrum to Gram‐positive bacteria and a limited number of Gram‐negative strains. Cefuroxim and amoxicillin/clavulanate, which also showed 3% resistances in our patients, cover a broader range of bacterial micro‐organisms. However, a broader coverage is not required in case of AD, as S. aureus is the most frequent bacterial micro‐organism causing skin infections.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>18557929</pmid><doi>10.1111/j.1600-0625.2008.00734.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0906-6705 |
| ispartof | Experimental dermatology, 2008-11, Vol.17 (11), p.953-957 |
| issn | 0906-6705 1600-0625 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69740472 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adolescent Adult Aged Allergic diseases Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use antimicrobial susceptibility atopic dermatitis Bacterial diseases Biological and medical sciences Child Child, Preschool Dermatitis, Atopic - complications Dermatology Drug Resistance, Bacterial Female Human bacterial diseases Humans Immunopathology Infant Infectious diseases Male Medical sciences Microbial Sensitivity Tests Middle Aged Retrospective Studies Skin allergic diseases. Stinging insect allergies Staphylococcal infections, streptococcal infections, pneumococcal infections Staphylococcal Skin Infections - complications Staphylococcal Skin Infections - drug therapy Staphylococcal Skin Infections - microbiology Staphylococcus aureus Staphylococcus aureus - drug effects Staphylococcus aureus - isolation & purification Vancomycin - pharmacology Vancomycin - therapeutic use Young Adult |
| title | Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A42%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotic%20treatment%20of%20cutaneous%20infections%20with%20Staphylococcus%20aureus%20in%20patients%20with%20atopic%20dermatitis:%20current%20antimicrobial%20resistances%20and%20susceptibilities&rft.jtitle=Experimental%20dermatology&rft.au=Niebuhr,%20Margarete&rft.date=2008-11&rft.volume=17&rft.issue=11&rft.spage=953&rft.epage=957&rft.pages=953-957&rft.issn=0906-6705&rft.eissn=1600-0625&rft_id=info:doi/10.1111/j.1600-0625.2008.00734.x&rft_dat=%3Cproquest_cross%3E69740472%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19660384&rft_id=info:pmid/18557929&rfr_iscdi=true |